Pharmacy alerts
-
National Patient Safety Alert
Shortage of bumetanide 1mg tablets.
-
UK Government restrictions on the use of Puberty Suppressing Hormones (Puberty Blockers) additional information for prescribers and pharmacists/dispensing doctors. Scotland
The Chief Medical Officer (CMO) and the Chief Pharmaceutical Officer (CPhO) for Scotland has issued a letter with additional information on the restrictions on use of puberty supressing hormones. This includes: Information on the NHS research study Summary of the restriction changes Buying GnRH analogues from unregulated sources Guidance on working with unregulated providers Support for children and young people affected by this change and Prescribing scenarios for prescribers and dispensers. The information can be found in the CMO’s letter. Details Date 3 Jul 2025
-
National Patient Safety Alert
Discontinuation of Promixin (colistimethate) 1-million unit powder for nebuliser solution unit dose vials
-
Original pack dispensing
From 1 January 2025, NHS community pharmacists and their teams can dispense up to 10% more or less than the quantity prescribed of eligible medicines on NHS prescriptions if it means the medicine can be dispensed in the manufacturer’s original packaging and if they follow the prescriber’s directions on the prescription. The regulations on what types of prescriptions can be dispensed or reimbursed differ between England, Scotland and Wales. Please read our guidance or check Community Pharmacy England, Community Pharmacy Scotland and Community Pharmacy Wales for more information on what the new rules apply to. Our guidance covers the changes, what the rules apply to, steps to use professional judgment and additional considerations. The guidance can be found on the RCPharm website.
-
National Patient Safety Alert
Shortage of Pancreatic enzyme replacement therapy (PERT) NatPSA/2024/013/DHSC – Additional actions.
-
Indefinite ban on the supply of puberty blockers
To children and young people under 18 years of age.